Key result
Intravenous administration of the endothelin-1 antagonist BQ-123 did not reduce myocardial infarct size compared to saline (29.2% vs 25.7% of the area at risk; p=0.70) in a dog model of ischemia.
Why the study?
Does intravenous BQ-123 reduce myocardial infarct size in a dog model of ischemia/reperfusion injury?
Population
Anaesthetised dogs with myocardial injury induced by 90 min of left circumflex coronary artery occlusion…
Comparison
Continuous intravenous infusion of BQ-123, begun… vs Saline treated animals
Design
Preclinical
Follow-up
4 hours of reperfusion
Authors
Loading...
Endothelin ETA blockade merits further study in ischaemia-reperfusion models; leaves open any clinical role in myocardial injury.
Does intravenous BQ-123 reduce myocardial infarct size in a dog model of ischemia/reperfusion injury?
Absolute Event Rate: 29.2% vs 25.7%
p-value: p=0.70
Intravenous administration of the endothelin-1 antagonist BQ-123 does not protect against ischemia/reperfusion injury in a canine model of acute coronary occlusion.
Krause et al. (1994) studied Myocardial ischaemic injury. BQ-123 vs. Saline was evaluated on Myocardial infarct size (% of the area at risk) (p=0.70). Intravenous administration of the endothelin-1 antagonist BQ-123 did not reduce myocardial infarct size compared to saline (29.2% vs 25.7% of the area at risk; p=0.70) in a dog model of ischemia.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: